You are here: Industry Insights > Translate

News List

Sanofi to Acquire Translate Bio for $3.2B contractpharma
August 05, 2021
Upgrades drug formulation capabilities and accelerates development of licensed programs in vaccines and potential to explore other therapeutic areas.
Sanofi to acquire mRNA therapies developer Translate Bio for $3.2bn pharmaceutical-technology
August 04, 2021
Sanofi has signed a definitive agreement to acquire 100% outstanding shares of a messenger RNA (mRNA) therapies company, Translate Bio, for a total equity value of nearly $3.2bn, or $38 per share in cash.
Sanofi plans €400m investment in mRNA vaccines ‘centre of excellence’ pharmatimes
June 30, 2021
French pharma company Sanofi has announced that it will invest €400m into a new facility focused on solely on the development and delivery of next-generation mRNA-based vaccines.
Phase I trial of mRNA-based influenza vaccine begins europeanpharmaceuticalreview
June 24, 2021
The trial will assess a monovalent mRNA-based vaccine candidate against seasonal influenza caused by the A/H3N2 strain.
Sanofi and Translate Bio start clinical trial for mRNA flu vaccine expresspharma
June 23, 2021
The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate worldpharmanews
March 19, 2021
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2 ...
mRNA COVID-19 vaccine from Sanofi will not ready this year: CEO expresspharma
February 18, 2021
A COVID-19 vaccine candidate developed by Sanofi and US group Translate Bio “will not be ready this year,” said the company’s CEO to Le Journal du Dimanche newspaper.